

AGENDA

08.30-09.00 **Coordinator address**

Robert Thimme - Universitätsklinikum Freiburg, Germany

09.00-09.30 **WP6 “Management, review and assessment” and WP7 “Dissemination, communication and exploitation activities”**

Marco Bargagna - ALTA Ricerca e Sviluppo in Biotecnologie Srlu, Italy

SCIENTIFIC SYMPOSIUM

09.30-10.00 **WP2 “Lipidomic analysis of HCC with different co-morbidities / gender”**

Task 2.1 To define the HCC lipidome and impact of co-morbidities

Presented by: Michael Wakelam - The Babraham Institute, UK

10.00-10.30 *Coffee break*

10.30-12.15 **WP3 “Viral co-morbidities on HCC disease pathways”**

Task 3.1 To discover the impact of viral infection on the hepatocellular transcriptome

Task 3.1B The role of HIF-1 α in the viral-host transcriptome

Task 3.3 Impact of viral infection on autotaxin-lysophosphatidic acid signalling pathway

Task 3.4 To validate viral-deregulated signalling pathways in HCC of different co-morbidities

Presented by: Jane McKeating - University of Birmingham, UK

Task 3.1A **HBx and HBc transcriptional activity**

Presented by: Ulrike Protzer - Helmholtz Zentrum München, Germany

Massimo Levrero - Institut National de la Santé Et de la Recherche Medicale, France

Task 3.2 **Impact of viral infection on hepatocellular phosphoproteome**

Presented by: Thomas Baumert - Institut National de la Santé Et de la Recherche Medicale, France

12.15-13.15 *Lunch*

13.15-13.45 **WPI “Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of comorbidities”**

Task 1.1 Sample collection

Task 1.2 Discover genomic alterations in HCC and association of known HCC drivers to co-morbidity and gender

Task 1.3 Transcriptomic profiling to assess co-morbidity and gender prevalence in HCC molecular classes and pathway activation

Presented by: Josep M Llovet - Consorci Institut d'Investigacions Biomèdiques August Pi I Sunyer, Spain

13.45-15.15 WP4 “Immune pathways contributing to HCC progression and control”

Task 4.1A To determine the mechanisms underlying T cell activation in NASH-HCC

Task 4.1B To define the role of lipids in activating T cells

Presented by: Mathias Heikenwälder - Deutsches Krebsforschungszentrum, Germany

Task 4.2 To phenotype tumour-specific T cell responses in HCC patients with differing co-morbidities

Task 4.3 Association of TAA-specific immunity with co-morbidity prior to HCC development

Task 4.4 To identify optimal checkpoint inhibitors for HCC immunotherapy

Presented by: Robert Thimme - Universitätsklinikum Freiburg, Germany

Task 4.5 To determine patient response to dendritic cell based therapy depending on co-morbidity

Presented by: David Adams - University of Birmingham, UK

15.15-16.00 Final discussion and summary

